Last reviewed · How we verify
Placebo of Isosorbide Dinitrate
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in clinical trials evaluating isosorbide dinitrate efficacy.
At a glance
| Generic name | Placebo of Isosorbide Dinitrate |
|---|---|
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
A placebo of isosorbide dinitrate contains no active drug substance and produces no direct pharmacological effect. It is used as a control in clinical trials to assess the efficacy of the active isosorbide dinitrate formulation by comparison. Any observed effects are attributable to placebo response rather than drug action.
Approved indications
- Control arm in clinical trials evaluating isosorbide dinitrate efficacy
Common side effects
Key clinical trials
- Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (PHASE1, PHASE2)
- Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies (PHASE3)
- Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT) (PHASE3)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease (PHASE2, PHASE3)
- Optimized Treatment of Pulmonary Edema or Congestion (PHASE4)
- Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor (PHASE4)
- Termination Of Anembryonic Pregnancy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: